About The Study: In this open-label extension of the ATTRibute-CM randomized clinical trial, early and continuous acoramidis treatment resulted in sustained incremental reductions in all-cause mortality, cardiovascular-related mortality, and first cardiovascular hospitalization through month 54. These findings support the importance of early and continuous long-term treatment with acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM).
Corresponding Author: To contact the corresponding author, Prem Soman, MD, PhD, email somanp@upmc.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2026.0819)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the American College of Cardiology 75th Annual Scientific Session & Expo.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2026.0819?guestAccessKey=9fcaf64c-f39e-42ed-b78d-3237e6eb30e8&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=033026
Journal
JAMA Cardiology